London Research & Pharmaceuticals

An independent biopharmaceutical research & development molecular foundry, Discovery Park, University of Western Ontario

Proprietary new drugs and candidates with improved efficacy and reduced toxicity as compared to current treatment options

250 years of combined research experience
Multiple pre-clinical trials completed and ongoing
Diverse pharmaceutical pipeline with strong efficacy and low toxicity

LRP Pipeline

LRP Sulfate Platform
LRP  661

Epilepsy

Late Stage Preclinical
Small molecule
Late Stage Preclinical
Small Molecule
LRP  666

Pain

Inflammation

PTSD/Anxiety

Early Stage Preclinical
Small molecule
Early Stage Preclinical
Small Molecule

Infectious Disease

Late Stage Preclinical
Small Molecule
Late Stage Preclinical
Small Molecule

Psychiatric disorders

Early Stage Preclinical
Small Molecule
Early Stage Preclinical
Small Molecule

Inflammatory Bowel Syndrome

Early Stage Preclinical
Small Molecule
Early Stage Preclinical
Small Molecule

Oncology

Early Stage Preclinical
Small Molecule
Early Stage Preclinical
Small Molecule

Leadership & Advisory Expertise

Global Pharmaceutical Development
Large Pharma Executive Experience
Regulatory
-  FDA, EMA
Governance
Finance
M & A
Private Equity
Public Markets
Strategy

Scientific Expertise

Organic Chemistry
Medicinal Chemistry
Chemical Engineering
Industrial Chemistry
Formulation Science
Medical Biophysics
Anesthesia Pain
Pharmacology
PharmD
Small & large animal expertise
Clinicaltrial Expertise
MD

Addressable Markets

Neurological Conditions

Anti-Inflammatory

Analgesics

Antibacterial

Oncology

Mental Health

Health & Wellness

From our NEWS

Recent News

Stay informed with the latest in press releases, and news stories.

Jun
10
//
2024

London Research & Pharmaceuticals (LRP) Presents

the Advancement of LRP-661, Their Lead Drug Candidate, at the Seventeenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII) Conference in Madrid, Spain, 5-8 May 2024
Mar
5
//
2024

London Research & Pharmaceuticals Presents

The advancement of LRP-661, their oral cannabidiol sulphate drug candidate at the prestigious Epilepsy Therapies & Diagnostics Development (ETDD) XVII conference in Miami

Contact Us  

Western University
Discovery Park, Stiller Centre
700 Collip Circle, Unit 213
London ON Canada N6G 4C4

Telephone: (519) 858-5049

Email Us
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
® All Rights Reserved London Research & Pharmaceuticals
Privacy Policy
Terms and Conditions